Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Biocorp    ALCOR   FR0012788065

BIOCORP

(ALCOR)
  Report
Delayed Quote. Delayed Euronext Alternext - 05/25 07:01:23 am
16.1 EUR   -0.62%
04/09BIOCORP : 2019 annual results
PU
04/09BIOCORP : 2019 Annual Results
BU
04/09BIOCORP : Annual results
CO
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Biocorp : Marketing partnership on Mallya with iSage Rx in the field of digital diabetes

share with twitter share with LinkedIn share with facebook
share via e-mail
02/19/2020 | 02:51pm EDT

Press release

BIOCORP: marketing partnership on Mallya with iSage Rx in the

field of digital diabetes

  • By combining Mallya's technology with the iSage Rx application, both parties offer patients with diabetes the most complete environment for monitoring

and follow-up of their pathology.

Issoire (France), Wilmington, DE (USA), February 19th, 2020, at 06:00 pm CET - BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization.

In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. The integration of Mallya (a CE- marked connected device dedicated to insulin pens) into the iSage app (a clinically validated insulin titration platform cleared by the FDA) should enable patients with type 2 diabetes to simplify their insulin management.

This will allow patients with diabetes to seamlessly capture, record, and store information about their insulin injections and while receiving automated guidance on how to adjust their insulin dose overtime ("titration").

Ryan Sysko, President and CEO of Amalgam Rx, Inc, said: "We are very pleased with this partnership to interface Mallya with our iSage app. Combining these two solutions offers to date the most powerful environment for diabetes digitalization and patient support. Together, we can simplify the often complex and confusing journey for patients starting on basal insulin. "

Éric Dessertenne, CEO of BIOCORP, concluded: "For patients with diabetes, the integration of Mallya and iSage provides an additional brick of information to improve their quality of life. For the community of diabetes, this integration is a powerful service platform that takes into account all the clinical and behavioral needs of patients. "

ABOUT ISAGE RX

iSage Rx, manufacturers of the iSage App, the first FDA 510(k)-cleared,prescription-only mobile application for the automated titration of all brands of basal insulin. iSage allows physicians to choose from multiple clinically-validated basal insulin algorithms and tailor the algorithms to the specific needs of their type 2 diabetes patients. iSage Rx is a wholly-owned subsidiary of Amalgam Rx. For more information, visit http://isageapp.com.

ABOUT AMALGAM RX

Amalgam Rx creates custom digital therapies that combine clinical and behavioral health and interventions to engage, support, and improve patient self-management. Led by an experienced team of physicians, behaviorists, technologists, and digital health pioneers, Amalgam Rx strives to use technology to accelerate the impact and scale of medicine to improve the lives of millions of people living with chronic disease. Amalgam does this by partnering

Press release

with leading life sciences companies to accelerate the R&D and commercialization of digital therapeutics. For more information, visit http://amalgamrx.com/.

ABOUT BIOCORP

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions.

BIOCORP is listed on Euronext since July 2015 (FR0012788065 - ALCOR). For more information, please visit www.biocorpsys.com.

Follow us on Twitter @BIOCORPSystems

AMALGAM RX CONTACT

Ryan Sysko

Chief Executive Officer rsysko@amalgamrx.com

BIOCORP CONTACTS

Jacques Gardette

Éric Dessertenne

Sylvaine Dessard

Chairman of the Board

Chief Executive Officer

Marketing & Communication Director

investisseurs@biocorp.fr

rp@biocorp.fr

+ 33 (0)6 88 69 72 85

ULYSSE COMMUNICATION CONTACTS

Bruno ARABIAN

Nicolas DANIELS

barabian@ulysse-communication.com

ndaniels@ulysse-communication.com

+33 (0)6 87 88 46 26

+33 (0)6 63 66 59 22

Disclaimer

Biocorp Production SA published this content on 19 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 February 2020 19:50:04 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOCORP
04/09BIOCORP : 2019 annual results
PU
04/09BIOCORP : 2019 Annual Results
BU
04/09BIOCORP : Annual results
CO
04/06BIOCORP : annual earnings release
02/19BIOCORP : Marketing partnership on Mallya with iSage Rx in the field of digital ..
PU
02/19BIOCORP : Marketing Partnership on Mallya with iSage Rx in the Field of Digital ..
BU
02/12BIOCORP : Strong Revenue Growth In 2019
BU
01/14BIOCORP : and SANOFI Strengthen Their Partnership With Mallya Smart Sensors
BU
01/09BIOCORP : 2020 financial calendar
PU
01/09BIOCORP : 2020 Financial Calendar
BU
More news
Financials (EUR)
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 108x
Capi. / Sales2019 -
Capi. / Sales2020 6,49x
Capitalization 66,9 M
Chart BIOCORP
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 25,00 €
Last Close Price 16,20 €
Spread / Highest target 54,3%
Spread / Average Target 54,3%
Spread / Lowest Target 54,3%
EPS Revisions
Managers
NameTitle
Eric Dessertenne Chief Executive Officer
Jacques Gardette Chairman
Stéphane Chabanais Chief Financial & Administrative Officer
Alain Marcoz Director-Software Research & Development
Emilie Gardette Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOCORP25.58%73
JOHNSON & JOHNSON-1.03%380 356
ROCHE HOLDING AG10.48%303 907
PFIZER, INC.-4.29%208 306
MERCK & CO., INC.-16.03%192 766
NOVARTIS AG-10.58%186 299